| Symbol | ALNY |
|---|---|
| Name | ALNYLAM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 675 WEST KENDALL STREET,HENRI A. TERMEER SQUARE, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 551-8200 |
| Fax | — |
| — | |
| Website | https://www.alnylam.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001178670 |
| Description | Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylams cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Additional info from NASDAQ: |
2026-06-25 13:00
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Read more
2026-06-11 06:30
GENESIS Pharma étend son partenariat commercial stratégique avec Alnylam Pharmaceuticals dans le domaine des thérapies fondées sur lARNi à la région nordique
Read more
2026-06-11 06:30
GENESIS Pharma erweitert strategische Vertriebspartnerschaft mit Alnylam Pharmaceuticals bei RNAi-Therapeutika auf skandinavische Länder
Read more
2026-06-11 02:52
GENESIS Pharma espande ad alcuni paesi scandinavi la collaborazione commerciale strategica con Alnylam Pharmaceuticals in materia di terapie RNAi
Read more
2026-06-11 02:46
GENESIS Pharma breidt strategisch commercieel partnerschap met Alnylam Pharmaceuticals voor RNAi-therapieën uit naar de Scandinavische regio
Read more
2026-06-11 02:41
GENESIS Pharma amplía su asociación comercial estratégica con Alnylam Pharmaceuticals para los tratamientos basados en ARNi a la región nórdica
Read more
2026-06-10 11:47
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
Read more
2026-06-03 20:45
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Read more
2026-06-03 20:25
Director PYOTT DAVID E I 🟡 adjusted position in 3.8K shares (1 derivative) of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $302.65 ($1.4M) Transaction Date: Jun 01, 2026 | Filing ID: 000048
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02939820 | Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloid… | — | TTR-mediated Amyloidosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05505838 | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-me… | — | Transthyretin-mediated Amyloidosis With Cardiomyopathy | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04056481 | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria | — | Acute Hepatic Porphyria | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04125472 | Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxa… | — | Primary Hyperoxaluria | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07636811 | A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Synd… | Phase2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Not_Yet_Recruiting | 2026-07-31 | 2031-07-23 | ClinicalTrials.gov |
| NCT07575308 | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female P… | Phase2 | Von Willebrand Disease (VWD) | Not_Yet_Recruiting | 2026-06-30 | 2028-11-29 | ClinicalTrials.gov |
| NCT07624071 | A Study to Evaluate ALN-6222 in Participants With Obesity | Phase1 | Obesity | Recruiting | 2026-06-04 | 2027-12-14 | ClinicalTrials.gov |
| NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hyper… | Phase2 | Hypertension | Recruiting | 2026-04-27 | 2028-10-01 | ClinicalTrials.gov |
| NCT07535606 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | Phase1 | Healthy Volunteers | Recruiting | 2026-03-02 | 2027-07-31 | ClinicalTrials.gov |
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Phase1 | Obesity | Recruiting | 2026-03-02 | 2028-03-02 | ClinicalTrials.gov |
| NCT07465224 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabe… | Phase2 | Type 2 Diabetes Mellitus (T2DM) | Recruiting | 2026-01-15 | 2027-05-28 | ClinicalTrials.gov |
| NCT07358078 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients… | — | Transthyretin Amyloidosis With Cardiomyopathy | Recruiting | 2026-01-09 | 2030-10-23 | ClinicalTrials.gov |
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patient… | Phase3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Recruiting | 2025-12-12 | 2031-06-12 | ClinicalTrials.gov |
| NCT07295717 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | Phase1 | Healthy Volunteers | Recruiting | 2025-12-12 | 2027-03-23 | ClinicalTrials.gov |
| NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Recruiting | 2025-10-15 | 2030-03-06 | ClinicalTrials.gov |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Ei… | Phase3 | High Risk Cardiovascular Disease | Recruiting | 2025-09-22 | 2030-09-30 | ClinicalTrials.gov |
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloi… | Phase3 | Transthyretin Amyloidosis With Cardiomyopathy | Recruiting | 2025-07-02 | 2032-11-30 | ClinicalTrials.gov |
| NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in O… | Phase1 | Obese or Overweight Healthy Volunteers | Active_Not_Recruiting | 2025-03-03 | 2027-08-31 | ClinicalTrials.gov |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase1 | Advanced Hepatocellular Carcinoma | Recruiting | 2024-12-30 | 2027-10-31 | ClinicalTrials.gov |
| NCT06679946 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With … | Phase3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Enrolling_By_Invitation | 2024-12-03 | 2028-03-31 | ClinicalTrials.gov |
| NCT06659640 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary… | Phase1 | Hereditary Hemorrhagic Telangiectasia | Recruiting | 2024-11-07 | 2028-06-22 | ClinicalTrials.gov |
| NCT06675565 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2024-11-05 | 2025-09-08 | ClinicalTrials.gov |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Phase1 | Huntington's Disease | Recruiting | 2024-10-14 | 2028-07-05 | ClinicalTrials.gov |
| NCT06423352 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hype… | Phase1 | Mild to Moderate Hypertension | Completed | 2024-06-05 | 2025-07-17 | ClinicalTrials.gov |
| NCT06393712 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | Phase2 | Cerebral Amyloid Angiopathy | Recruiting | 2024-05-17 | 2029-12-14 | ClinicalTrials.gov |
| NCT06360289 | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asympt… | — | Hereditary Amyloidosis, Transthyretin-Related | Active_Not_Recruiting | 2024-04-25 | 2027-12-01 | ClinicalTrials.gov |
| NCT06225544 | Lumasiran in Hyperoxalaemic Patients on Haemodialysis | Phase2 | Haemodialysis | Recruiting | 2024-04-14 | 2025-03-01 | ClinicalTrials.gov |
| NCT06272487 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hyp… | Phase2 | High Cardiovascular Risk | Completed | 2024-02-29 | 2025-12-01 | ClinicalTrials.gov |
| NCT05940922 | RWE-based Treatment Patterns and Outcomes in CIDP | — | Chronic Inflammatory Demyelinating Polyneuropathy | Unknown | 2023-08-17 | 2023-10-30 | ClinicalTrials.gov |
| NCT05761301 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers… | Phase1 | Type 2 Diabetes Mellitus (T2DM) | Terminated | 2023-03-10 | 2025-04-03 | ClinicalTrials.gov |
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Transthyretin-Mediated Amyloidosis | Completed | 2023-01-16 | 2025-09-30 | ClinicalTrials.gov |
| NCT05023889 | Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amylo… | Early_Phase1 | Polyneuropathies | Completed | 2022-08-03 | 2026-04-13 | ClinicalTrials.gov |
| NCT04569903 | Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-… | Early_Phase1 | Transthyretin Amyloidosis | Withdrawn | 2022-08-01 | 2025-02-01 | ClinicalTrials.gov |
| NCT05256810 | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout | Phase1 | Gout | Terminated | 2022-02-25 | 2023-01-25 | ClinicalTrials.gov |
| NCT05231785 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | Phase1 | Early-Onset Alzheimer Disease | Recruiting | 2022-02-04 | 2029-04-20 | ClinicalTrials.gov |
| NCT05161936 | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney S… | Phase2 | Recurrent Calcium Oxalate Kidney Stone Disease | Terminated | 2022-01-27 | 2022-11-01 | ClinicalTrials.gov |
| NCT04982393 | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxal… | — | Primary Hyperoxaluria Type 1 | Active_Not_Recruiting | 2021-12-13 | 2028-09-01 | ClinicalTrials.gov |
| NCT05103332 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Cont… | Phase2 | Hypertension | Completed | 2021-11-05 | 2024-09-13 | ClinicalTrials.gov |
| NCT04936035 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-M… | Phase2 | Hypertension | Completed | 2021-07-07 | 2024-12-05 | ClinicalTrials.gov |
| NCT04883905 | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Acute Hepatic Porphyria | Recruiting | 2021-04-26 | 2027-04-01 | ClinicalTrials.gov |
| NCT03999840 | Eculizumab to Cemdisiran Switch in aHUS | Phase2 | Atypical Hemolytic Uremic Syndrome | Withdrawn | 2021-01-01 | 2024-03-01 | ClinicalTrials.gov |
| NCT04561518 | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-… | — | Transthyretin-Mediated Amyloidosis | Recruiting | 2020-11-23 | 2033-12-31 | ClinicalTrials.gov |
| NCT04565717 | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcohol… | Phase1 | Nonalcoholic Steatohepatitis | Terminated | 2020-10-09 | 2023-12-21 | ClinicalTrials.gov |
| NCT05040373 | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | — | Hereditary Transthyretin-mediated (hATTR) Amyloidosis | Recruiting | 2020-08-01 | 2030-10-12 | ClinicalTrials.gov |
| NCT04152200 | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria T… | Phase3 | Primary Hyperoxaluria Type 1 | Completed | 2020-01-21 | 2025-06-23 | ClinicalTrials.gov |
| NCT04201418 | A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in… | — | Hereditary Transthyretin-mediated (ATTRv) Amyloidosis | Completed | 2019-12-18 | 2022-05-24 | ClinicalTrials.gov |
| NCT04153149 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloid… | Phase3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Active_Not_Recruiting | 2019-11-26 | 2026-12-02 | ClinicalTrials.gov |
| NCT03841448 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) | Phase2 | IgA Nephropathy (IgAN) | Terminated | 2019-09-30 | 2023-06-27 | ClinicalTrials.gov |
| NCT03997383 | APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyl… | Phase3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Completed | 2019-09-04 | 2025-12-24 | ClinicalTrials.gov |
| NCT03934307 | A Study to Evaluate ALN-AGT01 in Patients With Hypertension | Phase1 | Hypertension | Completed | 2019-05-01 | 2023-01-04 | ClinicalTrials.gov |
| NCT03905694 | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria T… | Phase3 | Primary Hyperoxaluria | Completed | 2019-04-22 | 2024-07-26 | ClinicalTrials.gov |
| NCT03862807 | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR… | Phase3 | Amyloidosis, Familial | Completed | 2019-03-27 | 2020-10-20 | ClinicalTrials.gov |
| NCT03759379 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Trans… | Phase3 | Amyloidosis, Hereditary | Completed | 2019-02-14 | 2025-11-05 | ClinicalTrials.gov |
| NCT03774784 | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (A… | — | Amyloidosis | Terminated | 2019-01-29 | 2020-05-18 | ClinicalTrials.gov |
| NCT03767829 | A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alph… | Phase1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | Terminated | 2018-12-05 | 2020-06-25 | ClinicalTrials.gov |
| NCT03681184 | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria… | Phase3 | Primary Hyperoxaluria Type 1 (PH1) | Completed | 2018-11-27 | 2024-01-12 | ClinicalTrials.gov |
| NCT03547297 | INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria … | — | Acute Hepatic Porphyria | Terminated | 2018-05-29 | 2019-01-15 | ClinicalTrials.gov |
| NCT03505853 | A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Coc… | Phase1 | Acute Intermittent Porphyria (AIP) | Completed | 2018-04-26 | 2019-01-10 | ClinicalTrials.gov |
| NCT03350451 | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Particip… | Phase2 | PH1 | Completed | 2018-04-04 | 2023-02-07 | ClinicalTrials.gov |
| NCT03338816 | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in… | Phase3 | Acute Hepatic Porphyria | Completed | 2017-11-16 | 2021-05-31 | ClinicalTrials.gov |
| NCT03303313 | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atyp… | Phase2 | Atypical Hemolytic Uremic Syndrome | Withdrawn | 2017-09-19 | 2018-09-12 | ClinicalTrials.gov |
| NCT03237494 | TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Moni… | — | Transthyretin Amyloidosis | Completed | 2017-07-20 | 2025-05-16 | ClinicalTrials.gov |
| NCT02949830 | A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS… | Phase1 | Acute Intermittent Porphyria | Completed | 2016-10-01 | 2021-11-05 | ClinicalTrials.gov |
| NCT02826018 | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With … | Phase1 | Hepatitis B | Terminated | 2016-06-24 | 2017-10-01 | ClinicalTrials.gov |
| NCT02797847 | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Hea… | Phase1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | Completed | 2016-06-07 | 2018-01-12 | ClinicalTrials.gov |
| NCT02706886 | Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Ty… | Phase1 | Primary Hyperoxaluria Type 1 (PH1) | Completed | 2016-03-08 | 2019-01-23 | ClinicalTrials.gov |
| NCT02595983 | The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment … | Phase2 | Transthyretin (TTR)-Mediated Amyloidosis | Completed | 2015-10-01 | 2017-02-06 | ClinicalTrials.gov |
| NCT02510261 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment … | Phase3 | Amyloidosis | Completed | 2015-07-16 | 2022-11-23 | ClinicalTrials.gov |
| NCT02503683 | A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Pati… | Phase1 | Antitrypsin Deficiency Liver Disease | Terminated | 2015-07-09 | 2018-01-03 | ClinicalTrials.gov |
| NCT02452372 | A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porp… | Phase1 | Acute Intermittent Porphyria | Completed | 2015-05-06 | 2017-09-06 | ClinicalTrials.gov |
| NCT02352493 | A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunte… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2015-01-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02314442 | A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevate… | Phase1 | Hypercholesterolemia | Completed | 2014-12-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02319005 | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With … | Phase3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Completed | 2014-12-01 | 2017-03-30 | ClinicalTrials.gov |
| NCT02292186 | A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyre… | Phase2 | TTR-mediated Amyloidosis | Completed | 2014-10-01 | 2017-02-22 | ClinicalTrials.gov |
| NCT02240784 | EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP) | — | Acute Hepatic Porphyria | Completed | 2014-08-01 | 2021-04-26 | ClinicalTrials.gov |
| NCT02252653 | DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspec… | — | Familial Amyloidotic Cardiomyopathy (FAC) | Completed | 2014-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02053454 | A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japane… | Phase1 | Transthyretin (TTR)-Mediated Amyloidosis | Completed | 2014-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01981837 | Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin … | Phase2 | TTR-mediated Amyloidosis | Completed | 2013-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01960348 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Tr… | Phase3 | TTR-mediated Amyloidosis | Completed | 2013-11-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01961921 | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Med… | Phase2 | TTR-mediated Amyloidosis | Completed | 2013-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01814839 | A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety… | Phase1 | TTR-mediated Amyloidosis | Completed | 2013-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01617967 | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloid… | Phase2 | TTR-mediated Amyloidosis | Completed | 2012-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01559077 | Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Hea… | Phase1 | TTR-mediated Amyloidosis | Completed | 2012-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01437059 | Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevate… | Phase1 | Elevated LDL-Cholesterol (LDL-C) | Completed | 2011-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01158079 | Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who H… | Phase1 | Solid Tumors | Completed | 2010-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01148953 | Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) A… | Phase1 | Transthyretin Mediated Amyloidosis (ATTR) | Completed | 2010-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01065935 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respirato… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2010-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00882180 | Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics an… | Phase1 | Solid Tumors | Completed | 2009-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00658086 | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respirator… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00496821 | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2007-07-01 | 2007-11-01 | ClinicalTrials.gov |
Total clinical trials: 90
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07624071 |
| ALN-6222 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07624071 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT06845202 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | NOT_YET_RECRUITING | NCT07636811 |
| Mivelsiran | Other | Phase PHASE2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | NOT_YET_RECRUITING | NCT07636811 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07624071 |
| ALN-6222 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07624071 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | NOT_YET_RECRUITING | NCT07636811 |
| Mivelsiran | Other | Phase PHASE2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | NOT_YET_RECRUITING | NCT07636811 |
| Placebo | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07624071 |
| ALN-6222 | Other | Phase PHASE1 | Obesity | NOT_YET_RECRUITING | NCT07624071 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | COMPLETED | NCT05023889 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | COMPLETED | NCT05023889 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | COMPLETED | NCT05023889 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | COMPLETED | NCT05023889 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | COMPLETED | NCT05023889 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | ACTIVE_NOT_RECRUITING | NCT06360289 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-6400 | Other | Phase PHASE2 | Von Willebrand Disease (VWD) | NOT_YET_RECRUITING | NCT07575308 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Patisiran | Other | Preclinical | Hereditary Transthyretin-mediated (ATTRv) Amyloidosis | COMPLETED | NCT04201418 |
| Lumasiran | Other | Preclinical | Primary Hyperoxaluria | APPROVED_FOR_MARKETING | NCT04125472 |
| patisiran (ALN-TTR02) | Other | Preclinical | TTR-mediated Amyloidosis | APPROVED_FOR_MARKETING | NCT02939820 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Transthyretin Mediated Amyloidosis (ATTR) | COMPLETED | NCT01148953 |
| ALN-TTR01 | Other | Phase PHASE1 | Transthyretin Mediated Amyloidosis (ATTR) | COMPLETED | NCT01148953 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Elevated LDL-Cholesterol (LDL-C) | COMPLETED | NCT01437059 |
| ALN-PCS02 | Other | Phase PHASE1 | Elevated LDL-Cholesterol (LDL-C) | COMPLETED | NCT01437059 |
| ALN-VSP02 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01158079 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01559077 |
| ALN-TTR02 | Other | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01559077 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | NCT02053454 |
| patisiran (ALN-TTR02) | Other | Phase PHASE1 | Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | NCT02053454 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT02314442 |
| ALN-PCSSC | Other | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT02314442 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01814839 |
| ALN-TTRSC (revusiran) | Other | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01814839 |
| Normal Saline | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
| ALN-RSV01 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02452372 |
| givosiran (ALN-AS1) | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02452372 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | COMPLETED | NCT02319005 |
| Revusiran (ALN-TTRSC) | Other | Phase PHASE3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | COMPLETED | NCT02319005 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | COMPLETED | NCT02797847 |
| ALN-TTRSC02 | Other | Phase PHASE1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | COMPLETED | NCT02797847 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02826018 |
| ALN-HBV | Other | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02826018 |
| Cemdisiran | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03303313 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Antitrypsin Deficiency Liver Disease | TERMINATED | NCT02503683 |
| ALN-AAT | Other | Phase PHASE1 | Antitrypsin Deficiency Liver Disease | TERMINATED | NCT02503683 |
| 5-probe cocktail | Other | Phase PHASE1 | Acute Intermittent Porphyria (AIP) | COMPLETED | NCT03505853 |
| Givosiran | Other | Phase PHASE1 | Acute Intermittent Porphyria (AIP) | COMPLETED | NCT03505853 |
| Revusiran | Other | Phase PHASE2 | Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | NCT02595983 |
| Placebo | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT02706886 |
| Lumasiran | Other | Phase PHASE1 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT02706886 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02352493 |
| ALN-CC5 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02352493 |
| Revusiran (ALN-TTRSC) | Other | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT02292186 |
| Placebos | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| cemdisiran | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| Placebo | Other | Phase PHASE1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | NCT03767829 |
| ALN-AAT02 | Other | Phase PHASE1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | NCT03767829 |
| Irbesartan-Matching Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| Irbesartan | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01-Matching Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01 | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-TTRSC (revusiran) for subcutaneous administration | Other | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01981837 |
| No intervention. Retrospective observation only. | Other | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy | UNKNOWN | NCT05940922 |
| Patisiran | Other | Phase PHASE3 | Amyloidosis | COMPLETED | NCT02510261 |
| Patisiran | Other | Preclinical | Transthyretin-mediated Amyloidosis With Cardiomyopathy | NO_LONGER_AVAILABLE | NCT05505838 |
| Givosiran | Other | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02949830 |
| Placebo | Other | Phase PHASE1 | Gout | TERMINATED | NCT05256810 |
| ALN-XDH | Other | Phase PHASE1 | Gout | TERMINATED | NCT05256810 |
| ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | Other | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01961921 |
| Patisiran | Other | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01617967 |
| Patisiran | Other | Phase PHASE3 | Amyloidosis, Familial | COMPLETED | NCT03862807 |
| Placebo | Other | Phase PHASE3 | Acute Hepatic Porphyria | COMPLETED | NCT03338816 |
| Givosiran | Other | Phase PHASE3 | Acute Hepatic Porphyria | COMPLETED | NCT03338816 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | TTR-mediated Amyloidosis | COMPLETED | NCT01960348 |
| patisiran (ALN-TTR02) | Other | Phase PHASE3 | TTR-mediated Amyloidosis | COMPLETED | NCT01960348 |
| Lumasiran | Other | Phase PHASE2 | PH1 | COMPLETED | NCT03350451 |
| Placebo | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis | TERMINATED | NCT04565717 |
| ALN-HSD | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis | TERMINATED | NCT04565717 |
| Givosiran | Other | Preclinical | Acute Hepatic Porphyria | APPROVED_FOR_MARKETING | NCT04056481 |
| Placebo | Other | Phase PHASE2 | Recurrent Calcium Oxalate Kidney Stone Disease | TERMINATED | NCT05161936 |
| Lumasiran | Other | Phase PHASE2 | Recurrent Calcium Oxalate Kidney Stone Disease | TERMINATED | NCT05161936 |
| Cemdisiran | Other | Phase PHASE2 | IgA Nephropathy (IgAN) | TERMINATED | NCT03841448 |
| Placebo | Other | Phase PHASE2 | IgA Nephropathy (IgAN) | TERMINATED | NCT03841448 |
| Lumasiran | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT03681184 |
| Placebo | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 (PH1) | COMPLETED | NCT03681184 |
| 0.9% Sodium Chloride (placebo) | Other | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| Lumasiran | Other | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| Lumasiran | Other | Phase PHASE3 | Primary Hyperoxaluria | COMPLETED | NCT03905694 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | TERMINATED | NCT05761301 |
| ALN-KHK | Other | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | TERMINATED | NCT05761301 |
| Lumasiran | Other | Phase PHASE3 | Primary Hyperoxaluria Type 1 | COMPLETED | NCT04152200 |
| Computer algorithm for ATTR | Other | Phase EARLY_PHASE1 | Transthyretin Amyloidosis | WITHDRAWN | NCT04569903 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06675565 |
| ALN-AGT01 RVR | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06675565 |
| Placebo | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| ALN-APP | Other | Phase PHASE1 | Early-Onset Alzheimer Disease | RECRUITING | NCT05231785 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Olmesartan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Amlodipine | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Indapamide | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| ALN-AGT01 | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04936035 |
| Placebo | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT04936035 |
| Standard of Care | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT06360289 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT04153149 |
| Vutrisiran | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT04153149 |
| Vutrisiran | Other | Phase PHASE3 | Amyloidosis, Hereditary | COMPLETED | NCT03759379 |
| Patisiran | Other | Phase PHASE3 | Amyloidosis, Hereditary | COMPLETED | NCT03759379 |
| patisiran | Other | Phase EARLY_PHASE1 | Polyneuropathies | ACTIVE_NOT_RECRUITING | NCT05023889 |
| Placebo | Other | Phase PHASE1 | Transthyretin-Mediated Amyloidosis | COMPLETED | NCT05661916 |
| ALN-TTRSC04 | Other | Phase PHASE1 | Transthyretin-Mediated Amyloidosis | COMPLETED | NCT05661916 |
| Vutrisiran | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | ENROLLING_BY_INVITATION | NCT06679946 |
| Placebo | Other | Phase PHASE2 | High Cardiovascular Risk | COMPLETED | NCT06272487 |
| Zilebesiran | Other | Phase PHASE2 | High Cardiovascular Risk | COMPLETED | NCT06272487 |
| Tirzepatide | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Placebo | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | Other | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Vutrisiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Nucresiran | Other | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| Patisiran | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | COMPLETED | NCT03997383 |
| Placebo | Other | Phase PHASE3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | COMPLETED | NCT03997383 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | Other | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| ALN-HTT02 | Other | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Placebo | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| ALN-6400 | Other | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Placebo | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE1 | Mild to Moderate Hypertension | COMPLETED | NCT06423352 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Zilebesiran | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| ALN-AGT01 RVR | Other | Phase PHASE2 | Hypertension | NOT_YET_RECRUITING | NCT07553442 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-5288 | Other | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| ALN-APP | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Placebo | Other | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| KPI-121 1.0% Ophthalmic Suspension | DRUG | Approved | Retinal Vein Occlusion | COMPLETED | NCT02245516 |
| Vehicle of KPI-121 Ophthalmic Suspension dosed BID | DRUG | Phase PHASE3 | Post Surgical Ocular Inflammation and Pain | COMPLETED | NCT02793817 |
| KPI-121 1% Ophthalmic Suspension dosed BID | DRUG | Phase PHASE3 | Post Surgical Ocular Inflammation and Pain | COMPLETED | NCT02793817 |
| Vehicle of KPI-121 0.25% Ophthalmic Suspension | DRUG | Phase PHASE3 | Dry Eye Syndromes | COMPLETED | NCT02819284 |
| KPI-121 0.25% Ophthalmic Suspension | DRUG | Approved | Retinal Vein Occlusion | COMPLETED | NCT02245516 |
| KPI-121 | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT02188160 |
| Vehicle | DRUG | Phase PHASE3 | Kerato Conjunctivitis Sicca | COMPLETED | NCT03616899 |
| KPI-121 Ophthalmic Suspension | DRUG | Phase PHASE3 | Kerato Conjunctivitis Sicca | COMPLETED | NCT03616899 |
| Oxycodone oral capsule | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| Placebo oral capsule | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| KP-1199 | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| buprenorphine sublingual film | DRUG | Phase PHASE1 | Opioid-use Disorder | COMPLETED | NCT04122755 |
| ALA-1000 | DRUG | Phase PHASE1 | Opioid-use Disorder | COMPLETED | NCT04122755 |
| loteprednol etabonate 0.25% ophthalmic suspension | DRUG | Phase PHASE4 | Corneal Endothelial Dystrophy | COMPLETED | NCT05136443 |
| KPI-012 Vehicle | DRUG | Phase PHASE2 | Persistent Corneal Epithelial Defect | TERMINATED | NCT05727878 |
| KPI-012 | DRUG | Phase PHASE2 | Persistent Corneal Epithelial Defect | TERMINATED | NCT05727878 |
| escitalopram, sertraline, duloxetine or venlafaxine XR | DRUG | Phase PHASE1 | Treatment Resistant Depression | COMPLETED | NCT06965569 |
| ALA-3000 | DRUG | Phase PHASE1 | Treatment Resistant Depression | COMPLETED | NCT06965569 |
| Tirzepatide | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-4285 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-5288 | DRUG | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Nucresiran | DRUG | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| ALN-4324 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-AGT01 RVR | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06675565 |
| ALN-6400 | DRUG | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | DRUG | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-HTT02 | DRUG | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Standard of Care | OTHER | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT06360289 |
| 0.9% Sodium Chloride (placebo) | DRUG | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| No intervention. Retrospective observation only. | OTHER | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy | UNKNOWN | NCT05940922 |
| ALN-KHK | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | TERMINATED | NCT05761301 |
| ALN-TTRSC04 | DRUG | Phase PHASE1 | Transthyretin-Mediated Amyloidosis | COMPLETED | NCT05661916 |
| ALN-XDH | DRUG | Phase PHASE1 | Gout | TERMINATED | NCT05256810 |
| ALN-APP | DRUG | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Zilebesiran | DRUG | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Olmesartan | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Amlodipine | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Indapamide | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| patisiran | DRUG | Phase EARLY_PHASE1 | Polyneuropathies | ACTIVE_NOT_RECRUITING | NCT05023889 |
| Computer algorithm for ATTR | DEVICE | Phase EARLY_PHASE1 | Transthyretin Amyloidosis | WITHDRAWN | NCT04569903 |
| ALN-HSD | DRUG | Phase PHASE1 | Nonalcoholic Steatohepatitis | TERMINATED | NCT04565717 |
| Placebos | DRUG | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| cemdisiran | DRUG | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| Irbesartan-Matching Placebo | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| Irbesartan | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01-Matching Placebo | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01 | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT04936035 |
| ALN-AAT02 | DRUG | Phase PHASE1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | NCT03767829 |
| Vutrisiran | DRUG | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| 5-probe cocktail | DRUG | Phase PHASE1 | Acute Intermittent Porphyria (AIP) | COMPLETED | NCT03505853 |
| Cemdisiran | DRUG | Phase PHASE2 | IgA Nephropathy (IgAN) | TERMINATED | NCT03841448 |
| Givosiran | DRUG | Preclinical | Acute Hepatic Porphyria | APPROVED_FOR_MARKETING | NCT04056481 |
| ALN-HBV | DRUG | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02826018 |
| ALN-TTRSC02 | DRUG | Phase PHASE1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | COMPLETED | NCT02797847 |
| Placebo | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT02188160 |
| Lumasiran | DRUG | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| Revusiran | DRUG | Phase PHASE2 | Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | NCT02595983 |
| ALN-AAT | DRUG | Phase PHASE1 | Antitrypsin Deficiency Liver Disease | TERMINATED | NCT02503683 |
| givosiran (ALN-AS1) | DRUG | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02452372 |
| ALN-CC5 | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02352493 |
| ALN-PCSSC | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT02314442 |
| Revusiran (ALN-TTRSC) | DRUG | Phase PHASE3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | COMPLETED | NCT02319005 |
| ALN-TTRSC (revusiran) for subcutaneous administration | DRUG | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01981837 |
| ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | DRUG | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01961921 |
| patisiran (ALN-TTR02) | DRUG | Preclinical | TTR-mediated Amyloidosis | APPROVED_FOR_MARKETING | NCT02939820 |
| ALN-TTRSC (revusiran) | DRUG | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01814839 |
| Patisiran | DRUG | Preclinical | Transthyretin-mediated Amyloidosis With Cardiomyopathy | NO_LONGER_AVAILABLE | NCT05505838 |
| ALN-TTR02 | DRUG | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01559077 |
| ALN-PCS02 | DRUG | Phase PHASE1 | Elevated LDL-Cholesterol (LDL-C) | COMPLETED | NCT01437059 |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| ALN-TTR01 | DRUG | Phase PHASE1 | Transthyretin Mediated Amyloidosis (ATTR) | COMPLETED | NCT01148953 |
| Normal Saline | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
| ALN-VSP02 | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01158079 |
| normal saline | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT00658086 |
| ALN-RSV01 | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
Total products: 730